YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance
YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this re...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Szulzewsky, Frank [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
17 |
|---|
| Übergeordnetes Werk: |
Enthalten in: 326 oral DOSE RESPONSE OF NORMAL LUNG DURING RT ASSESSED BY CONE BEAM CT – A POTENTIAL TOOL FOR BIOLOGICALLY ADAPTIVE RADIATION THERAPY - 2011, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:475 ; year:2021 ; pages:205-221 ; extent:17 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ydbio.2020.12.018 |
|---|
| Katalog-ID: |
ELV053895460 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV053895460 | ||
| 003 | DE-627 | ||
| 005 | 20230626035438.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210910s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ydbio.2020.12.018 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001381.pica |
| 035 | |a (DE-627)ELV053895460 | ||
| 035 | |a (ELSEVIER)S0012-1606(21)00004-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 570 |a 540 |q VZ |
| 100 | 1 | |a Szulzewsky, Frank |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance |
| 264 | 1 | |c 2021transfer abstract | |
| 300 | |a 17 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions. | ||
| 520 | |a YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions. | ||
| 650 | 7 | |a YAP1 |2 Elsevier | |
| 650 | 7 | |a YAP1 fusion |2 Elsevier | |
| 650 | 7 | |a Hippo signaling pathway |2 Elsevier | |
| 650 | 7 | |a Gene fusions |2 Elsevier | |
| 650 | 7 | |a Cancer |2 Elsevier | |
| 700 | 1 | |a Holland, Eric C. |4 oth | |
| 700 | 1 | |a Vasioukhin, Valeri |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |t 326 oral DOSE RESPONSE OF NORMAL LUNG DURING RT ASSESSED BY CONE BEAM CT – A POTENTIAL TOOL FOR BIOLOGICALLY ADAPTIVE RADIATION THERAPY |d 2011 |g Amsterdam [u.a.] |w (DE-627)ELV010652000 |
| 773 | 1 | 8 | |g volume:475 |g year:2021 |g pages:205-221 |g extent:17 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ydbio.2020.12.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_147 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_2034 | ||
| 951 | |a AR | ||
| 952 | |d 475 |j 2021 |h 205-221 |g 17 | ||
| author_variant |
f s fs |
|---|---|
| matchkey_str |
szulzewskyfrankhollandericcvasioukhinval:2021----:a1nisuinrtisnacrntainrgesoad |
| hierarchy_sort_str |
2021transfer abstract |
| publishDate |
2021 |
| allfields |
10.1016/j.ydbio.2020.12.018 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001381.pica (DE-627)ELV053895460 (ELSEVIER)S0012-1606(21)00004-X DE-627 ger DE-627 rakwb eng 610 VZ 570 540 VZ Szulzewsky, Frank verfasserin aut YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance 2021transfer abstract 17 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions. YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions. YAP1 Elsevier YAP1 fusion Elsevier Hippo signaling pathway Elsevier Gene fusions Elsevier Cancer Elsevier Holland, Eric C. oth Vasioukhin, Valeri oth Enthalten in Elsevier 326 oral DOSE RESPONSE OF NORMAL LUNG DURING RT ASSESSED BY CONE BEAM CT – A POTENTIAL TOOL FOR BIOLOGICALLY ADAPTIVE RADIATION THERAPY 2011 Amsterdam [u.a.] (DE-627)ELV010652000 volume:475 year:2021 pages:205-221 extent:17 https://doi.org/10.1016/j.ydbio.2020.12.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_147 GBV_ILN_2018 GBV_ILN_2034 AR 475 2021 205-221 17 |
| spelling |
10.1016/j.ydbio.2020.12.018 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001381.pica (DE-627)ELV053895460 (ELSEVIER)S0012-1606(21)00004-X DE-627 ger DE-627 rakwb eng 610 VZ 570 540 VZ Szulzewsky, Frank verfasserin aut YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance 2021transfer abstract 17 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions. YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions. YAP1 Elsevier YAP1 fusion Elsevier Hippo signaling pathway Elsevier Gene fusions Elsevier Cancer Elsevier Holland, Eric C. oth Vasioukhin, Valeri oth Enthalten in Elsevier 326 oral DOSE RESPONSE OF NORMAL LUNG DURING RT ASSESSED BY CONE BEAM CT – A POTENTIAL TOOL FOR BIOLOGICALLY ADAPTIVE RADIATION THERAPY 2011 Amsterdam [u.a.] (DE-627)ELV010652000 volume:475 year:2021 pages:205-221 extent:17 https://doi.org/10.1016/j.ydbio.2020.12.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_147 GBV_ILN_2018 GBV_ILN_2034 AR 475 2021 205-221 17 |
| allfields_unstemmed |
10.1016/j.ydbio.2020.12.018 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001381.pica (DE-627)ELV053895460 (ELSEVIER)S0012-1606(21)00004-X DE-627 ger DE-627 rakwb eng 610 VZ 570 540 VZ Szulzewsky, Frank verfasserin aut YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance 2021transfer abstract 17 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions. YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions. YAP1 Elsevier YAP1 fusion Elsevier Hippo signaling pathway Elsevier Gene fusions Elsevier Cancer Elsevier Holland, Eric C. oth Vasioukhin, Valeri oth Enthalten in Elsevier 326 oral DOSE RESPONSE OF NORMAL LUNG DURING RT ASSESSED BY CONE BEAM CT – A POTENTIAL TOOL FOR BIOLOGICALLY ADAPTIVE RADIATION THERAPY 2011 Amsterdam [u.a.] (DE-627)ELV010652000 volume:475 year:2021 pages:205-221 extent:17 https://doi.org/10.1016/j.ydbio.2020.12.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_147 GBV_ILN_2018 GBV_ILN_2034 AR 475 2021 205-221 17 |
| allfieldsGer |
10.1016/j.ydbio.2020.12.018 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001381.pica (DE-627)ELV053895460 (ELSEVIER)S0012-1606(21)00004-X DE-627 ger DE-627 rakwb eng 610 VZ 570 540 VZ Szulzewsky, Frank verfasserin aut YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance 2021transfer abstract 17 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions. YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions. YAP1 Elsevier YAP1 fusion Elsevier Hippo signaling pathway Elsevier Gene fusions Elsevier Cancer Elsevier Holland, Eric C. oth Vasioukhin, Valeri oth Enthalten in Elsevier 326 oral DOSE RESPONSE OF NORMAL LUNG DURING RT ASSESSED BY CONE BEAM CT – A POTENTIAL TOOL FOR BIOLOGICALLY ADAPTIVE RADIATION THERAPY 2011 Amsterdam [u.a.] (DE-627)ELV010652000 volume:475 year:2021 pages:205-221 extent:17 https://doi.org/10.1016/j.ydbio.2020.12.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_147 GBV_ILN_2018 GBV_ILN_2034 AR 475 2021 205-221 17 |
| allfieldsSound |
10.1016/j.ydbio.2020.12.018 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001381.pica (DE-627)ELV053895460 (ELSEVIER)S0012-1606(21)00004-X DE-627 ger DE-627 rakwb eng 610 VZ 570 540 VZ Szulzewsky, Frank verfasserin aut YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance 2021transfer abstract 17 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions. YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions. YAP1 Elsevier YAP1 fusion Elsevier Hippo signaling pathway Elsevier Gene fusions Elsevier Cancer Elsevier Holland, Eric C. oth Vasioukhin, Valeri oth Enthalten in Elsevier 326 oral DOSE RESPONSE OF NORMAL LUNG DURING RT ASSESSED BY CONE BEAM CT – A POTENTIAL TOOL FOR BIOLOGICALLY ADAPTIVE RADIATION THERAPY 2011 Amsterdam [u.a.] (DE-627)ELV010652000 volume:475 year:2021 pages:205-221 extent:17 https://doi.org/10.1016/j.ydbio.2020.12.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_147 GBV_ILN_2018 GBV_ILN_2034 AR 475 2021 205-221 17 |
| language |
English |
| source |
Enthalten in 326 oral DOSE RESPONSE OF NORMAL LUNG DURING RT ASSESSED BY CONE BEAM CT – A POTENTIAL TOOL FOR BIOLOGICALLY ADAPTIVE RADIATION THERAPY Amsterdam [u.a.] volume:475 year:2021 pages:205-221 extent:17 |
| sourceStr |
Enthalten in 326 oral DOSE RESPONSE OF NORMAL LUNG DURING RT ASSESSED BY CONE BEAM CT – A POTENTIAL TOOL FOR BIOLOGICALLY ADAPTIVE RADIATION THERAPY Amsterdam [u.a.] volume:475 year:2021 pages:205-221 extent:17 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
YAP1 YAP1 fusion Hippo signaling pathway Gene fusions Cancer |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
326 oral DOSE RESPONSE OF NORMAL LUNG DURING RT ASSESSED BY CONE BEAM CT – A POTENTIAL TOOL FOR BIOLOGICALLY ADAPTIVE RADIATION THERAPY |
| authorswithroles_txt_mv |
Szulzewsky, Frank @@aut@@ Holland, Eric C. @@oth@@ Vasioukhin, Valeri @@oth@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
ELV010652000 |
| dewey-sort |
3610 |
| id |
ELV053895460 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV053895460</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626035438.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ydbio.2020.12.018</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001381.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV053895460</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0012-1606(21)00004-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Szulzewsky, Frank</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">17</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">YAP1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">YAP1 fusion</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hippo signaling pathway</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Gene fusions</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Holland, Eric C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vasioukhin, Valeri</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="t">326 oral DOSE RESPONSE OF NORMAL LUNG DURING RT ASSESSED BY CONE BEAM CT – A POTENTIAL TOOL FOR BIOLOGICALLY ADAPTIVE RADIATION THERAPY</subfield><subfield code="d">2011</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV010652000</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:475</subfield><subfield code="g">year:2021</subfield><subfield code="g">pages:205-221</subfield><subfield code="g">extent:17</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ydbio.2020.12.018</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2018</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">475</subfield><subfield code="j">2021</subfield><subfield code="h">205-221</subfield><subfield code="g">17</subfield></datafield></record></collection>
|
| author |
Szulzewsky, Frank |
| spellingShingle |
Szulzewsky, Frank ddc 610 ddc 570 Elsevier YAP1 Elsevier YAP1 fusion Elsevier Hippo signaling pathway Elsevier Gene fusions Elsevier Cancer YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance |
| authorStr |
Szulzewsky, Frank |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV010652000 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 570 - Life sciences; biology 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 570 540 VZ YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance YAP1 Elsevier YAP1 fusion Elsevier Hippo signaling pathway Elsevier Gene fusions Elsevier Cancer Elsevier |
| topic |
ddc 610 ddc 570 Elsevier YAP1 Elsevier YAP1 fusion Elsevier Hippo signaling pathway Elsevier Gene fusions Elsevier Cancer |
| topic_unstemmed |
ddc 610 ddc 570 Elsevier YAP1 Elsevier YAP1 fusion Elsevier Hippo signaling pathway Elsevier Gene fusions Elsevier Cancer |
| topic_browse |
ddc 610 ddc 570 Elsevier YAP1 Elsevier YAP1 fusion Elsevier Hippo signaling pathway Elsevier Gene fusions Elsevier Cancer |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
e c h ec ech v v vv |
| hierarchy_parent_title |
326 oral DOSE RESPONSE OF NORMAL LUNG DURING RT ASSESSED BY CONE BEAM CT – A POTENTIAL TOOL FOR BIOLOGICALLY ADAPTIVE RADIATION THERAPY |
| hierarchy_parent_id |
ELV010652000 |
| dewey-tens |
610 - Medicine & health 570 - Life sciences; biology 540 - Chemistry |
| hierarchy_top_title |
326 oral DOSE RESPONSE OF NORMAL LUNG DURING RT ASSESSED BY CONE BEAM CT – A POTENTIAL TOOL FOR BIOLOGICALLY ADAPTIVE RADIATION THERAPY |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV010652000 |
| title |
YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance |
| ctrlnum |
(DE-627)ELV053895460 (ELSEVIER)S0012-1606(21)00004-X |
| title_full |
YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance |
| author_sort |
Szulzewsky, Frank |
| journal |
326 oral DOSE RESPONSE OF NORMAL LUNG DURING RT ASSESSED BY CONE BEAM CT – A POTENTIAL TOOL FOR BIOLOGICALLY ADAPTIVE RADIATION THERAPY |
| journalStr |
326 oral DOSE RESPONSE OF NORMAL LUNG DURING RT ASSESSED BY CONE BEAM CT – A POTENTIAL TOOL FOR BIOLOGICALLY ADAPTIVE RADIATION THERAPY |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
zzz |
| container_start_page |
205 |
| author_browse |
Szulzewsky, Frank |
| container_volume |
475 |
| physical |
17 |
| class |
610 VZ 570 540 VZ |
| format_se |
Elektronische Aufsätze |
| author-letter |
Szulzewsky, Frank |
| doi_str_mv |
10.1016/j.ydbio.2020.12.018 |
| dewey-full |
610 570 540 |
| title_sort |
yap1 and its fusion proteins in cancer initiation, progression and therapeutic resistance |
| title_auth |
YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance |
| abstract |
YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions. |
| abstractGer |
YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions. |
| abstract_unstemmed |
YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_147 GBV_ILN_2018 GBV_ILN_2034 |
| title_short |
YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance |
| url |
https://doi.org/10.1016/j.ydbio.2020.12.018 |
| remote_bool |
true |
| author2 |
Holland, Eric C. Vasioukhin, Valeri |
| author2Str |
Holland, Eric C. Vasioukhin, Valeri |
| ppnlink |
ELV010652000 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.ydbio.2020.12.018 |
| up_date |
2024-07-06T20:12:43.007Z |
| _version_ |
1803861898566828032 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV053895460</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626035438.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ydbio.2020.12.018</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001381.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV053895460</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0012-1606(21)00004-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Szulzewsky, Frank</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">17</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">YAP1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">YAP1 fusion</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hippo signaling pathway</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Gene fusions</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Holland, Eric C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vasioukhin, Valeri</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="t">326 oral DOSE RESPONSE OF NORMAL LUNG DURING RT ASSESSED BY CONE BEAM CT – A POTENTIAL TOOL FOR BIOLOGICALLY ADAPTIVE RADIATION THERAPY</subfield><subfield code="d">2011</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV010652000</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:475</subfield><subfield code="g">year:2021</subfield><subfield code="g">pages:205-221</subfield><subfield code="g">extent:17</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ydbio.2020.12.018</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2018</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">475</subfield><subfield code="j">2021</subfield><subfield code="h">205-221</subfield><subfield code="g">17</subfield></datafield></record></collection>
|
| score |
7.3996973 |